Dr. Slovin on Approaches of Immunotherapy in Prostate Cancer

Susan F. Slovin, MD, PhD
Published: Wednesday, Aug 16, 2017



Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses approaches of immunotherapy for patients with prostate cancer.

It’s important to recognize that immunotherapy encompasses more than checkpoint inhibitors, explains Slovin. There is a wide variety of other approaches that fall under the category of immunotherapy, such as antibodies, chimeric antigen receptor T cells, and DNA vaccines.
 


Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses approaches of immunotherapy for patients with prostate cancer.

It’s important to recognize that immunotherapy encompasses more than checkpoint inhibitors, explains Slovin. There is a wide variety of other approaches that fall under the category of immunotherapy, such as antibodies, chimeric antigen receptor T cells, and DNA vaccines.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x